News

Microbion, co-located in Vancouver, BC and Bozeman, MT, is a clinical stage biopharmaceutical company specializing in the treatment of hard to treat and antibiotic-resistant infections. Microbion's lead compound,

BMS’ immuno-oncology agent Opdivo will now be assessed with Janssen’s Darzalex in multiple myeloma, as well as several solid tumor types including including non-small cell lung cancer, pancreatic cancer,

HCC is the most common form of liver cancer, a disease that affects nearly 40,000 patients in the United States and is the second deadliest form of cancer

APT Therapeutics has applied proprietary protein engineering strategies to develop APT102, an innovative human apyrase therapy for the treatment of thrombotic diseases. Uniquely different than current FDA-approved antithrombotic

Duzallo, which is a fixed-dose combination of lesinurad and allopurinol, is intended to treat hyperuricemia in patients with uncontrolled gout. The drug is likely to be commercially launched in

In this study, patients with type 2 diabetes uncontrolled on stable, maximal metformin therapy treated with IONIS-GCGR achieved robust and sustained, statistically significant improvements in hemoglobin A1c (HbA1c)

In addition, Shire’s former MRT employees, the group focused on the development of this technology since 2008, have joined RaNA to continue to advance the platform with lead

The randomized, double-blind, vehicle controlled phase 3 confirmatory study included 744 patients. The primary endpoint of statistically significant improvement in Schirmer's score (a measurement of tear production) was

The clinical trial is evaluating the efficacy and safety of Quisinostat in platinum-resistant ovarian cancer in combination with Paclitaxel and Carboplatin. The detailed results will be presented in